HRAS and neoplasm: For instance, tipifarnib and other FTIs have been suggested to act as antiangiogenic agents in several tumor types including HNSCC [40,46], but the mechanisms are yet to be elucidated [44] and may be hard to delineate from indirect downstream consequences of inhibiting another target, such as HRAS [40].